GSK Pharma declares Rs 57 dividend at 101st AGM

GlaxoSmithKline Pharmaceuticals Limited has approved a dividend of Rs 57 per share for the financial year ended March 31, 2026, at its 101st Annual General Meeting (AGM). The meeting, held on June 30, 2026, through video conferencing, saw shareholders adopt the audited financial statements and ratify the remuneration for the cost auditor for FY26 and FY27. All six resolutions listed in the notice dated May 13, 2026, were passed with the requisite majority.

Voting Results

The voting process was conducted via remote e-voting from June 26, 2026, to June 29, 2026, and through e-voting during the AGM. P. N. Parikh of Parikh & Associates served as the scrutinizer. The total number of shareholders on the record date of June 23, 2026, was 132,132.

Resolution Summary

Sr No	Agenda	Resolution Type	Result
1	Adoption of Audited Financial Statements for FY26	Ordinary	Passed with requisite majority
2	Dividend of Rs 57 per share for FY26	Ordinary	Passed with requisite majority
3	Re-appointment of Director Mr. Subesh Williams	Ordinary	Passed with requisite majority
4	Commission to Independent Directors	Special	Passed with requisite majority
5	Ratification of Cost Auditor Remuneration for FY26	Ordinary	Passed with requisite majority
6	Ratification of Cost Auditor Remuneration for FY27	Ordinary	Passed with requisite majority

Shareholder Participation

A total of 142,505,574 votes were polled on the resolution regarding the ratification of the cost auditor's remuneration for FY26. The Promoter and Promoter Group cast 127,054,524 votes in favour across all resolutions. Public Institutions and Public Non-Institutions also participated, with votes cast in favour exceeding 99% for most items.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.23%	+2.47%	+11.12%	+3.01%	-27.51%	+63.49%

GlaxoSmithKline Pharmaceuticals has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of ₹3.54 crores. The company stated on June 25, 2026, that the demand includes ₹1.23 crores towards the alleged overcharging amount and ₹2.31 crores as interest. GlaxoSmithKline Pharmaceuticals clarified that the order will have no impact on its financial operations and confirmed it will file an appeal against the demand.

Demand Notice Details

The notice, dated June 24, 2026, alleges that the company overcharged in the sale of scheduled formulations by fixing prices higher than those notified by the government or the NPPA. The breakdown of the total demand is detailed below:

Parameter	Details
Authority	National Pharmaceutical Pricing Authority
Nature of Notice	Demand Notice
Date of Notice	June 24, 2026
Total Demand Amount	₹3,54,12,025
Alleged Overcharging	₹1,22,91,163
Interest	₹2,31,20,862

Regulatory Implications

The demand notice was issued under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The specific violation cited involves charging prices higher than the fixed or notified government price during the relevant period. The company has disclosed that it intends to challenge the order through an appeal.